Alcoholic liver disease (ALD) shows up on Step questions in a very “pattern recognition” way: AST > ALT, fatty change vs hepatitis vs cirrhosis, painful hepatomegaly, and a patient who may minimize alcohol use. If you can connect the timeline of drinking → histologic injury → clinical findings → labs/complications, you’ll pick up a lot of easy points on both Step 1 and Step 2.
Where Alcoholic Liver Disease Fits (and Why Step Loves It)
Alcoholic liver disease = a spectrum of progressive hepatic injury due to chronic ethanol exposure:
- Steatosis (fatty liver) – earliest, reversible
- Alcoholic hepatitis (steatohepatitis) – inflammatory injury with hepatocyte ballooning
- Cirrhosis – end-stage fibrosis + regenerative nodules → portal HTN and liver failure
First Aid cross-reference (Step 1):
- GI → Liver pathology: fatty change, alcoholic hepatitis (Mallory bodies), cirrhosis
- Biochem/nutrition tie-ins: thiamine deficiency, folate deficiency, malnutrition
- Pharm/toxicology tie-ins: acetaminophen risk, CYP induction, withdrawal treatment
Definition (Quick and Testable)
Alcoholic liver disease is liver injury caused by chronic alcohol intake, classically:
- Men: ~> 60–80 g ethanol/day for years
- Women: ~> 20–40 g/day for years (more susceptible due to lower gastric ADH, body water differences)
High-yield nuance: Women develop ALD at lower total doses and over shorter durations.
Pathophysiology: What Ethanol Does to the Liver
1) Ethanol metabolism shifts redox state
Ethanol is metabolized mainly via:
- Alcohol dehydrogenase (ADH): ethanol → acetaldehyde
- Aldehyde dehydrogenase (ALDH): acetaldehyde → acetate
- MEOS (CYP2E1): inducible pathway (important for drug interactions)
Both ADH and ALDH generate NADH, increasing the NADH/NAD⁺ ratio.
Consequences of ↑ NADH/NAD⁺ (Step 1 favorite):
- Inhibits -oxidation of fatty acids and promotes triglyceride synthesis → steatosis
- Drives pyruvate → lactate → lactic acidosis
- Depletes pyruvate available for gluconeogenesis → fasting hypoglycemia
- Alters lipid handling → hypertriglyceridemia, fatty liver
2) Acetaldehyde is directly toxic
Acetaldehyde:
- Forms adducts with proteins → hepatocyte injury
- Promotes lipid peroxidation and oxidative stress
- Triggers inflammation (Kupffer cells → cytokines like TNF-α)
3) CYP2E1 induction increases oxidative stress + drug toxicity
Chronic alcohol induces CYP2E1, raising reactive oxygen species and increasing conversion of some drugs to toxic metabolites.
Classic clinical tie-in: chronic alcohol use increases risk of acetaminophen hepatotoxicity (more NAPQI generation + low glutathione in malnutrition).
4) Stellate cell activation → fibrosis → cirrhosis
Inflammation and oxidative stress activate hepatic stellate (Ito) cells → collagen deposition (especially in perisinusoidal/“chicken-wire” areas) → bridging fibrosis → cirrhosis.
Morphology & Histology: What You’re Supposed to Recognize
Steatosis (fatty change)
- Gross: enlarged, yellow, greasy liver
- Micro: macrovesicular fat droplets in hepatocytes
- Clinical: often asymptomatic; mild RUQ discomfort; mild transaminitis
- Reversible with abstinence (days to weeks)
Alcoholic hepatitis
Key pathology:
- Hepatocyte ballooning degeneration
- Mallory-Denk bodies (clumped keratin intermediate filaments)
- Neutrophils around injured hepatocytes (“satellitosis”)
- Perivenular/pericellular fibrosis can begin here
High-yield warning: Mallory bodies are classically associated with alcoholic hepatitis but are not exclusive (can be seen in NASH, Wilson disease, cholestatic disorders).
Cirrhosis
- Diffuse bridging fibrosis + regenerative nodules
- Leads to portal hypertension and liver synthetic failure
Board-friendly progression: fatty liver → hepatitis → cirrhosis (not everyone progresses, but risk rises with sustained heavy use).
Clinical Presentation: How It Shows Up in Vignettes
Steatosis
- Often incidental (mild hepatomegaly, mild AST/ALT elevation)
- Improves rapidly with abstinence
Alcoholic hepatitis (classic Step 2 presentation)
- Fever
- Tender hepatomegaly
- Jaundice
- Malaise, anorexia, weight loss
- May have ascites/encephalopathy if severe
Cirrhosis complications (Step 1 + Step 2)
Portal HTN:
- Ascites
- Splenomegaly → thrombocytopenia
- Varices (esophageal/gastric) → massive hematemesis
- Caput medusae, hemorrhoids (less emphasized clinically)
Synthetic failure:
- Coagulopathy (↑ PT/INR due to ↓ clotting factors; factor VII falls early)
- Hypoalbuminemia → edema/ascites
- Hepatic encephalopathy (asterixis, confusion)
Endocrine/skin stigmata:
- Spider angiomas, palmar erythema
- Gynecomastia, testicular atrophy (↑ estrogen due to impaired metabolism)
- Dupuytren contracture can be associated with chronic alcoholism
Cancer risk:
- Cirrhosis (any cause) increases risk of hepatocellular carcinoma (HCC).
Diagnosis: Labs, Patterns, and “Buzzword” Ratios
High-yield lab pattern: AST > ALT (but not astronomically high)
- Alcoholic liver disease: AST:ALT ≥ 2:1 is classic
- Absolute values often < 500 U/L
- Mechanisms:
- Alcohol causes mitochondrial injury → AST released (AST has mitochondrial isoenzyme)
- Alcoholics often have pyridoxal phosphate (B6) deficiency, which depresses ALT activity more than AST
Other supportive labs
- ↑ GGT (gamma-glutamyl transferase): inducible by alcohol; supportive but nonspecific
- ↑ bilirubin, ↑ INR, ↓ albumin if severe or cirrhotic
- Macrocytosis (↑ MCV) from alcohol toxicity/folate deficiency
Distinguish from viral hepatitis (common trap)
| Feature | Alcoholic hepatitis | Acute viral hepatitis |
|---|---|---|
| AST/ALT ratio | ≥ 2:1 | Typically < 1 |
| AST/ALT level | Often < 500 | Can be > 1000 |
| Histology | Mallory bodies, neutrophils | Lymphocytes, apoptotic bodies (Councilman) |
| Clinical | Fever, tender hepatomegaly, jaundice | Viral prodrome, jaundice |
Imaging and biopsy (real-world vs boards)
- Ultrasound: fatty infiltration, nodular liver, ascites; rules out biliary obstruction
- Biopsy: not always necessary but can confirm alcoholic hepatitis if diagnosis is unclear
Severity Scoring (Step 2 / Shelf-Style)
You don’t need to memorize every formula, but know why they matter:
- Maddrey Discriminant Function (DF): identifies severe alcoholic hepatitis → consider steroids
- MELD: estimates mortality in chronic liver disease; transplant planning
- Lille score: response to steroids in alcoholic hepatitis
High-yield clinical logic: Severe alcoholic hepatitis with high short-term mortality may be treated with corticosteroids if no contraindications.
Treatment: What Actually Changes Outcomes
The foundation: alcohol cessation + nutrition
- Absolute abstinence is the most important intervention at every stage
- Nutritional support (high protein unless encephalopathy; refeeding carefully)
- Thiamine before glucose in malnourished patients to avoid precipitating Wernicke encephalopathy
Alcoholic hepatitis (moderate–severe)
- Supportive care + treat complications (electrolytes, infection screen, GI bleed)
- Corticosteroids (e.g., prednisolone) for severe disease if eligible
- Contraindications commonly tested: active GI bleeding, uncontrolled infection/sepsis, pancreatitis, renal failure (institution-dependent), uncontrolled diabetes
Cirrhosis management (complication-based)
- Ascites: spironolactone ± furosemide, sodium restriction; therapeutic paracentesis + albumin if large-volume
- Variceal bleeding prophylaxis: nonselective beta-blocker (propranolol/nadolol/carvedilol)
- Acute variceal bleed: octreotide + endoscopic banding + prophylactic antibiotics (e.g., ceftriaxone)
- Encephalopathy: lactulose (targets ammonia via trapping as NH4⁺) ± rifaximin
- SBP: treat with third-gen cephalosporin; prophylaxis in high-risk patients
- HCC surveillance in cirrhosis: ultrasound ± AFP every 6 months (often tested conceptually)
Transplant considerations (Step-relevant principles)
- Best long-term option for decompensated cirrhosis
- Candidates require careful psychosocial evaluation; many centers use an abstinence period, though practices vary
High-Yield Associations & Classic Vignette Hooks
“AST > ALT, ratio > 2”
- Think alcoholic hepatitis, especially if values are moderately elevated (not in the thousands)
Mallory-Denk bodies + neutrophils
- Alcoholic hepatitis pathology pairing
Chronic alcohol + acetaminophen = danger
- CYP2E1 induction + low glutathione → hepatotoxicity risk
Alcohol use + pancreatitis + hepatitis
- Alcohol commonly causes acute pancreatitis; it can coexist with ALD and change management (e.g., steroid contraindication in some settings)
Alcoholism + nutrition deficiencies
- Thiamine deficiency: Wernicke-Korsakoff risk
- Folate deficiency: macrocytic anemia
- Magnesium deficiency: worsens hypokalemia, arrhythmias; impairs PTH release
Don’t confuse with NAFLD/NASH
Both can cause steatosis/steatohepatitis, but:
- NAFLD/NASH: metabolic syndrome, diabetes, obesity; AST/ALT often < 1 or near 1 (not the classic 2:1 pattern)
Rapid Review: Step-Style Takeaways
- ALD spectrum: steatosis (reversible) → alcoholic hepatitis → cirrhosis
- Biochem core: ↑ NADH/NAD⁺ → steatosis, lactic acidosis, hypoglycemia
- Lab hallmark: AST:ALT ≥ 2:1, typically < 500
- Histology: Mallory-Denk bodies, neutrophils, ballooning degeneration
- Big complications: portal HTN (varices, ascites, splenomegaly), liver failure (INR, albumin), encephalopathy, HCC risk
- Best treatment: abstinence + nutrition; severe alcoholic hepatitis may need steroids if no contraindications